TY - JOUR

T1 - The protocol

T2 - Influence of the combination carriage CYP2C19*2 and *17 on efficacy of clopidogrel

AU - Zelenskaya, E. M.

AU - Barbarash, O. L.

AU - Ganyukov, V. I.

AU - Kochergin, N. A.

AU - Apartsin, K. A.

AU - Gorokhova, A. V.

AU - Papeshina, S. A.

AU - Nikolaev, K. Yu

AU - Batueva, K. Yu

AU - Yankovskaya, S. V.

AU - Tronin, O. V.

AU - Lifshits, G. I.

PY - 2017

Y1 - 2017

N2 - Aim. To assess the association of efficacy and safety endpoints with simultaneous carriage of polymorphic variants of the gene CYP2C19: rs4244285 (*2), and rs12248560 (*17) in treatment with clopidogrel. Material and methods. In the study, 289 patients included, from large cities of Siberia, underwent coronary stenting for acute coronary syndrome. All participants were assessed for alleles CYP2C19*2, *3, *17, and clinical outcomes were followed for 30 days (thrombotic complications, bleedings). Results. It was found that simultaneous carriage of CYP2C19*2 and CYP2C19*17 alleles is associated with the risk of serious adverse events development of thrombotic origin comparing to the absence of such polymorphism carriage (p=0,016), and with general adverse events risk related to insufficiency of clopidogrel action (p=0,046). Conclusion. According to the study results, subjects with the *2/*17 carriage should be classified to a delayed clopidogrel metabolism group, as in the group definite and probable stent thrombosis were found significantly more prevalent.

AB - Aim. To assess the association of efficacy and safety endpoints with simultaneous carriage of polymorphic variants of the gene CYP2C19: rs4244285 (*2), and rs12248560 (*17) in treatment with clopidogrel. Material and methods. In the study, 289 patients included, from large cities of Siberia, underwent coronary stenting for acute coronary syndrome. All participants were assessed for alleles CYP2C19*2, *3, *17, and clinical outcomes were followed for 30 days (thrombotic complications, bleedings). Results. It was found that simultaneous carriage of CYP2C19*2 and CYP2C19*17 alleles is associated with the risk of serious adverse events development of thrombotic origin comparing to the absence of such polymorphism carriage (p=0,016), and with general adverse events risk related to insufficiency of clopidogrel action (p=0,046). Conclusion. According to the study results, subjects with the *2/*17 carriage should be classified to a delayed clopidogrel metabolism group, as in the group definite and probable stent thrombosis were found significantly more prevalent.

KW - Clopidogrel

KW - CYP2C19

KW - Stent thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85035046182&partnerID=8YFLogxK

U2 - 10.15829/1560-4071-2017-10-113-117

DO - 10.15829/1560-4071-2017-10-113-117

M3 - Article

AN - SCOPUS:85035046182

VL - 150

SP - 113

EP - 117

JO - Российский кардиологический журнал

JF - Российский кардиологический журнал

SN - 1560-4071

IS - 10

ER -